Cocrystal Pharma Stock Net Asset
| COCP Stock | USD 1.50 0.07 4.90% |
Cocrystal Pharma fundamentals help investors to digest information that contributes to Cocrystal Pharma's financial success or failures. It also enables traders to predict the movement of Cocrystal Stock. The fundamental analysis module provides a way to measure Cocrystal Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cocrystal Pharma stock.
Cocrystal | Net Asset |
Cocrystal Pharma Company Net Asset Analysis
Cocrystal Pharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Cocrystal Pharma Net Asset | 31.26 M |
Most of Cocrystal Pharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cocrystal Net Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Cocrystal Pharma is extremely important. It helps to project a fair market value of Cocrystal Stock properly, considering its historical fundamentals such as Net Asset. Since Cocrystal Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cocrystal Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cocrystal Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Cocrystal Total Assets
Total Assets |
|
Based on the recorded statements, Cocrystal Pharma has a Net Asset of 31.26 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Cocrystal Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.Cocrystal Pharma is currently under evaluation in net asset category among related companies.
Cocrystal Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Cocrystal Pharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Cocrystal Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cocrystal Pharma's value.| Shares | Ubs Group Ag | 2023-12-31 | 167 | Wells Fargo & Co | 2023-12-31 | 92.0 | Nvwm, Llc | 2023-12-31 | 84.0 | Royal Bank Of Canada | 2023-12-31 | 9.0 | Fmr Inc | 2023-12-31 | 4.0 | Parallel Advisors, Llc | 2023-09-30 | 0.0 | Clean Yield Group Inc | 2023-09-30 | 0.0 | Archer Investment Corporation | 2023-12-31 | 0.0 | Advisor Group Holdings, Inc. | 2023-09-30 | 0.0 | Vanguard Group Inc | 2023-12-31 | 275.7 K | Renaissance Technologies Corp | 2023-12-31 | 125.1 K |
Cocrystal Fundamentals
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | (9.95 M) | ||||
| Shares Outstanding | 10.17 M | ||||
| Shares Owned By Insiders | 30.03 % | ||||
| Shares Owned By Institutions | 6.70 % | ||||
| Number Of Shares Shorted | 4.96 K | ||||
| Price To Earning | 193.33 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 92.45 X | ||||
| Gross Profit | (8.79 M) | ||||
| EBITDA | (22.55 M) | ||||
| Net Income | (17.98 M) | ||||
| Cash And Equivalents | 51.03 M | ||||
| Cash Per Share | 6.28 X | ||||
| Total Debt | 1.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 18.34 X | ||||
| Book Value Per Share | 2.59 X | ||||
| Cash Flow From Operations | (14.67 M) | ||||
| Short Ratio | 0.32 X | ||||
| Earnings Per Share | (1.87) X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 15.01 M | ||||
| Total Asset | 31.26 M | ||||
| Retained Earnings | (315.91 M) | ||||
| Working Capital | 25.83 M | ||||
| Current Asset | 6.75 M | ||||
| Current Liabilities | 3.15 M | ||||
| Net Asset | 31.26 M |
About Cocrystal Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cocrystal Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cocrystal Pharma's short interest history, or implied volatility extrapolated from Cocrystal Pharma options trading.
Pair Trading with Cocrystal Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Cocrystal Stock
| 0.64 | EQ | Equillium Financial Report 9th of May 2024 | PairCorr |
| 0.6 | DNTH | Dianthus Therapeutics Symbol Change | PairCorr |
| 0.53 | VERA | Vera Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.47 | VCEL | Vericel Corp Ord Downward Rally | PairCorr |
| 0.46 | VINC | Vincerx Pharma Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.
The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cocrystal Pharma Piotroski F Score and Cocrystal Pharma Altman Z Score analysis. To learn how to invest in Cocrystal Stock, please use our How to Invest in Cocrystal Pharma guide.Note that the Cocrystal Pharma information on this page should be used as a complementary analysis to other Cocrystal Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Cocrystal Stock analysis
When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Cocrystal Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cocrystal Pharma. If investors know Cocrystal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cocrystal Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Revenue Per Share 0.006 | Quarterly Revenue Growth 0.269 | Return On Assets (0.37) | Return On Equity (0.55) |
The market value of Cocrystal Pharma is measured differently than its book value, which is the value of Cocrystal that is recorded on the company's balance sheet. Investors also form their own opinion of Cocrystal Pharma's value that differs from its market value or its book value, called intrinsic value, which is Cocrystal Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cocrystal Pharma's market value can be influenced by many factors that don't directly affect Cocrystal Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cocrystal Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cocrystal Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cocrystal Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.